POEMS Syndrome
The pathogenesis of POEMS syndrome involves the overproduction of pro-inflammatory cytokines and abnormal angiogenesis. Our company is at the forefront of drug and therapy development for POEMS syndrome, aiming to provide innovative therapeutics development solutions.
Overview of POEMS Syndrome
POEMS syndrome, also known as Crow-Fukase syndrome, Takatsuki disease, osteosclerotic myeloma, or PEP syndrome, is a rare paraneoplastic syndrome that is often associated with plasma cell dyscrasia. The acronym POEMS stands for polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes, which are the key clinical manifestations of this syndrome. The exact cause of POEMS syndrome is not yet fully understood, but it is believed to be related to the overproduction of certain cytokines, including vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6).
Fig.1 Representative bone marrow morphological features of POEMS syndrome. (Bou Zerdan M., et al., 2022)
Therapy Discovery and Development for POEMS Syndrome
Monoclonal antibodies targeting specific molecules have emerged as a promising therapeutic approach for POEMS syndrome. Anti-CD38 monoclonal antibodies, such as daratumumab and isatuximab, have shown effectiveness in the therapeutic of relapsed multiple myeloma (MM) and light chain amyloidosis. Additionally, bevacizumab, an anti-VEGF monoclonal antibody, has shown benefits in certain cases when combined with alkylator therapy or preceding therapy. CAR-T cell therapy, a groundbreaking immunotherapy approach, has also shown remarkable success in the therapeutic of relapsed and refractory multiple myeloma.
At our company, we are committed to pushing the boundaries of diagnostics and therapy development for POEMS syndrome. The following links showcase the diverse therapeutic development services we can provide, and we hope you will find a solution that satisfies you.
Our Services
The development of reliable animal models and in vitro models is crucial for studying the pathogenesis of POEMS syndrome and evaluating potential therapeutic interventions. Our experienced scientists are well-versed in the establishment and characterization of animal models that mimic the key features of POEMS syndrome. By using these models, we can better provide you with a one-stop POEMS syndrome therapy development service.
Polyneuropathy Animal Models
We have expertise in generating animal models that exhibit polyneuropathy similar to what is observed in cases with POEMS syndrome. By utilizing these models, we can investigate the underlying mechanisms of nerve damage, and evaluate potential neuroprotective therapies.
Organomegaly Animal Models
Organomegaly, characterized by enlargement of organs such as the liver, spleen, and lymph nodes, is a prominent feature of POEMS syndrome. Our company specializes in the development of animal models that mimic organomegaly observed in POEMS syndrome.
Endocrinopathy Animal Models
Endocrine abnormalities, such as hypogonadism, thyroid dysfunction, and adrenal insufficiency, are common in POEMS syndrome. We have the expertise to develop animal models that exhibit endocrinopathy similar to what is observed in cases with POEMS syndrome.
Monoclonal Gammopathy Models
Monoclonal gammopathy, characterized by the presence of abnormal proteins in the blood, is a key diagnostic criterion for POEMS syndrome. Our company offers animal model development services for studying monoclonal gammopathy in POEMS syndrome.
Skin Change Animal Models
Skin changes, including hyperpigmentation, hemangiomas, and thickened skin, are common in POEMS syndrome. Our company specializes in the development of animal models that mimic the skin changes observed in cases with POEMS syndrome.
In Vitro Models
We provide cell-based models such as peripheral neural cells, endothelial cells and immune cells, as well as organoid model development services such as neural, lymph node and endocrine tissue to support in vitro research.
We offer comprehensive preclinical research services, including drug screening, efficacy testing, and safety evaluation. In addition to the extensive array of services and models mentioned earlier, our proficiency extends to tailoring personalized solutions and creating disease models that precisely cater to your specific requirements. We take pride in our ability to adapt and customize our offerings to meet your unique needs. If our comprehensive range of services has captured your attention, we sincerely welcome you to reach out to us without any hesitation.
References
- Bou Zerdan M., et al. "Recent advances in the treatment and supportive care of POEMS syndrome." Journal of Clinical Medicine 11.23 (2022): 7011.
- Kim, Yu Ri. "Update on the POEMS syndrome." Blood research 57.Suppl 1 (2022): 27.